Next Article in Journal
Epidemiological Scenario of American Trypanosomiasis and Its Socioeconomic and Environmental Relations, Pará, Eastern Brazilian Amazon
Next Article in Special Issue
Desiccation Tolerance of Aedes aegypti and Aedes albopictus Eggs of Northeastern Argentina Origin
Previous Article in Journal
Neonatal Mucormycosis: A Rare but Highly Lethal Fungal Infection in Term and Preterm Newborns—A 20-Year Systematic Review
Previous Article in Special Issue
Estimating Dengue Outbreak Thresholds in West Africa: A Comprehensive Analysis of Climatic Influences in Burkina Faso, 2018–2024
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Assessing Insect Growth Regulator Resistance Using Bioassays: A Systematic Review and Meta-Analysis of Methoprene and Pyriproxyfen Inhibition of Emergence in Three Vector Mosquito Species

North Shore Mosquito Abatement District, 117 Northfield Rd, Northfield, IL 60093, USA
*
Authors to whom correspondence should be addressed.
Trop. Med. Infect. Dis. 2025, 10(4), 87; https://doi.org/10.3390/tropicalmed10040087
Submission received: 26 February 2025 / Revised: 24 March 2025 / Accepted: 26 March 2025 / Published: 28 March 2025

Abstract

:
This systematic review and meta-analysis aims to: (1) characterize the distribution of published inhibition of emergence (IE50, IE90, and IE95) reference values for pyriproxyfen and methoprene in Culex pipiens [L.], Aedes aegypti [L.], and Aedes albopictus [Skuse]; (2) generate combined-effect IE values using a DerSimonian and Laird (DL) random-effects model to establish benchmarks for future resistance assessments; and (3) compare these combined-effect IE values with previously published literature. A systematic search was conducted in PubMed, SciELO, J-STAGE, and Google Scholar up to 10 February 2025, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Eligible studies were primary, peer-reviewed literature that aligned with World Health Organization (WHO) protocols for insect growth regulator (IGR) resistance testing, specifically those reporting susceptible reference IE values from continuous immersion dose-response bioassays analyzed using probit regression. A total of 72 unique studies that aligned with WHO protocols were assessed for publication bias using a funnel plot and Egger’s regression. Sensitivity and subgroup analyses were conducted to evaluate individual study contributions to the overall combined effect. Heterogeneity (I2) and combined effect values were estimated for 18 different species/active ingredient/IE concentration subgroup pairings. Heterogeneity (I2) ranged from 29.32 to 99.78% between the 18 subgroups, indicating inconsistency within the literature. The DL combined effect IE50 varied from 0.048 ppb for Cx. pipiens exposed to pyriproxyfen to 1.818 ppb for Ae. albopictus exposed to methoprene. A certainty analysis indicated that 1 combined effect value exhibited high certainty, 8 out of 18 pairings were moderately certain, 6 exhibited low certainty and 3 exhibited very low certainty. The main causes of uncertainty (ranked) were inconsistency between studies, imprecision of the combined effect size, and possible publication bias. Our findings indicate that (1) robust DL combined effect IE50 values could be established for all species/IGR pairings, providing essential benchmarks for future resistance assessments; (2) substantial heterogeneity among susceptible laboratory colonies complicates resistance detection in field-collected mosquitoes; and (3) a significant portion of the literature relies on reference mosquito strains that are likely not fully susceptible, further complicating resistance detection. This study was not registered and was supported by the North Shore Mosquito Abatement District.

1. Introduction

Mosquito-borne diseases remain a global public health burden, with increasing mortality and morbidity rates anticipated because of globalization and climate change [1,2,3]. The mosquitoes, Culex pipiens [L.], Aedes aegypti [L.], and Aedes albopictus [Skuse] are globally invasive vector mosquitoes which together have been implicated in various outbreaks of Zika, chikungunya, West Nile virus, and dengue fever [1,2]. Some notable examples of outbreaks caused by these mosquitoes include 1868 cases and 89 deaths attributed to West Nile virus in Dallas, Texas, in 2012, vectored by Cx. pipiens quinquefasciatus [Say], over 42,000 locally acquired cases of Zika in Puerto Rico and the US territories in 2016 and 2017 vectored by Ae. aegypti, and a 2005 outbreak of chikungunya vectored by Ae. albopictus on the island of Réunion which saw over 250,000 cases [1,2]. Due to the absence of widely available preventive vaccines or prophylactic treatments, mosquito population abundance reduction remains a central strategy for many vector control programs. For over a century, mosquitoes have faced various selective pressures from chemical interventions aimed at reducing populations and mitigating the risk of disease transmission [4,5]. Larval mosquito control has long been recognized as a vital element in any strategy for population management and diverse classes of larvicides have been developed to support this objective [6]. Not surprisingly, resistance to nearly every class of larvicide has been observed around the world both in wild populations as well as laboratory-selected colonies [7,8].
Insect growth regulators (IGRs), such as methoprene and pyriproxyfen, were first developed and introduced in the 1970s as “third-generation” pesticides [9,10,11]. These pesticides were designed to offer greater selectivity, fewer non-target effects, and a reduced likelihood of resistance development [7,12,13,14]. By interfering with gene expression during metamorphosis, the juvenoid IGRs can prevent the development and successful emergence of adult mosquitoes [15,16]. Despite the reduced potential for resistance, a variety of reports over recent decades provide overwhelming evidence that, even for juvenoid IGRs, the development of resistance is possible in wild mosquito populations [7,8].
To maintain an arsenal of effective larval control materials, it is necessary for public health and other vector control programs to periodically assess wild populations of mosquitoes for susceptibility to existing or potential control materials. The most widely utilized methodology for assessing IGR susceptibility requires a phenotypic bioassay methodology where susceptible larval mosquitoes (most commonly a laboratory-maintained “reference” colony) and field-collected mosquito populations are exposed to a range of concentrations of the IGR in parallel with untreated controls [17,18]. Corrected mortality at each concentration is subjected to a probit regression analysis to determine the concentration of IGR that inhibits emergence (IE) of 50, 90, 95%, etc., of larval mosquitoes (i.e., IE50, IE90 and/or IE95).
The baseline “reference” value derived from this procedure can then be used to develop a “discriminating dose” or “diagnostic dose”. For example, the World Health Organization (WHO) recommends two times the IE99.9 (the concentration that causes inhibition of emergence in 99.9% of exposed larvae) of a susceptible reference strain as a diagnostic dose [17]. The diagnostic dose can then be applied to field-collected mosquitoes to determine susceptibility as compared to the reference strain. This method reduces the dependence on a reference colony, which is especially important in geographies or for species where a reference colony may be unavailable. Alternatively, a ratio can be calculated which, most commonly, compares the IE50 value of field-collected mosquitoes to that of the susceptible reference strain to create a resistance ratio or “RR” [19]. The WHO has identified resistance ratios at the IE50 of <5 as indicating susceptible field populations; an RR between 5 and 10 indicates moderate resistance, and an RR > 10 indicates high resistance [18]. For both the diagnostic dose method and the resistance ratio method, the susceptible reference IE value serves as the only baseline for comparison and so the reliability of this value is critically important for understanding the presence and intensity of resistance that may exist.
WHO standard assessments of mosquito susceptibility to IGR larvicides rely entirely on mathematical comparisons to a baseline susceptible reference IE value. As a result, variability in reference measurements—whether due to bias, experimental errors, or biological differences between reference colonies—can obscure resistance detection or lead to inaccurate assessments of its intensity. For instance, if a susceptible reference colony has an IE50 value that is too high, the resulting RR calculation will be artificially low. The relationship between the reference IE values and the resulting RR follows a rectangular hyperbola, where small changes in the denominator (susceptible IE values) can cause disproportionately large shifts in RR.
Any resistance assessment based on an inaccurate reference baseline risks leading to inappropriate treatment decisions, reduced field effectiveness, or even treatment failures. Although the WHO has published protocols intended to standardize the experimental conditions for deriving reference IE values, the extremely wide variation in published reference IE values significantly limits the interpretation of resistance assessments and complicates comparisons between studies and regions. In addition, the WHO does not report pre-established standard IE values for susceptible mosquito populations. This necessitates individual research groups acquire susceptible strains, maintain said mosquito strain in colony, and evaluate for insecticide susceptibility. The lack of comparability and reliability in susceptible reference measurements has important ramifications for public health and mitigating the threat posed by mosquito vectors of disease. Therefore, understanding the range and variability in published reference values is crucial for evaluating the validity and reliability of experimentally derived IE values, as well as for assessing the ongoing susceptibility of reference colonies maintained globally. Given these challenges, our study aims to systematically assess and synthesize reference IE values to improve the reliability of IGR resistance assessments.
The specific goals of this systematic review and meta-analysis are threefold. First, we aim to summarize and characterize the distribution of published susceptible reference IE values (IE50, IE90, and/or IE95) for three globally invasive vector mosquito species (Cx. pipiens, Ae. aegypti, and Ae. albopictus) and two IGRs (methoprene and pyriproxyfen). Second, we aim to generate composite IE values for each species, IE value, and IGR using a DerSimonian and Laird random-effects model. A robust susceptible reference value, synthesized from multiple studies, can serve as a crucial benchmark for public health and vector control professionals to assess susceptibility in field-collected mosquitoes, evaluate the suitability of mosquitoes for use as susceptible references, and assess or monitor the continued susceptibility of laboratory colonies. These values can be used when access to or maintaining a reference colony is unattainable, a common barrier in the mosquito control field [20], or to validate susceptibility of existing strains. Finally, we aim to compare synthesized IE values with previously published susceptible reference values to contextualize the existing literature and highlight trends or discrepancies in resistance assessment.

2. Methods

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 standard guidelines were used to address the main goals of this study [21,22]. The PICO framework was used as follows: Population = pesticide-susceptible laboratory colony mosquitoes intended as a susceptible control or reference population. Intervention = exposure to the insect growth regulators methoprene or pyriproxyfen in a bioassay aligned with WHO protocols;. Comparison = variability in baseline susceptibility reported across the literature. Outcome = IE50, IE90, and/or IE95 values derived from a probit-based analysis [23]. This meta-analysis was not prospectively registered, as it did not assess a specific hypothesis, treatment effect, or treatment efficacy but instead aimed to examine the variability in control values from previously published research. Given this study’s focus on methodology rather than hypothesis testing or treatment effect quantification, prospective registration was not deemed necessary.

2.1. Literature Search Strategy

The goal of the literature search was to identify reference emergence of inhibition concentrations (IE50, IE90, and/or IE95 values) from three vector species of pesticide-susceptible laboratory mosquitoes exposed to the insect growth regulators methoprene or pyriproxyfen derived using a WHO-aligned dose/concentration-response bioassay. Both authors independently conducted a systematic search of internet databases to identify relevant publication records. Four databases were queried between 3 September 2024 and 10 February 2025: PubMed (last searched 7 February 2025), SciELO (last searched 7 February 2025), J-STAGE (last searched 7 February 2025), and Google Scholar (last searched 10 February 2025). The following keywords and combinations of keywords were used:
PubMed, SciELO, and J-STAGE search terms:
“Aedes aegypti” AND “methoprene” OR “pyriproxyfen” OR “s-31183”
“Aedes albopictus” AND “methoprene” OR “pyriproxyfen” OR “s-31183”
“Culex” AND “methoprene” OR “pyriproxyfen” OR “s-31183”
Google Scholar search terms:
“Aedes aegypti” OR “Aedes albopictus” OR “Culex” AND “Methoprene” OR “pyriproxyfen” OR ““s-31183” AND “emergence inhibition” AND “probit”
There were no search limitations imposed for date or language of publication. All search keywords were evaluated against the full text of the article record. All identified records were independently screened by title and abstract by both authors. Unpublished manuscripts, conference abstracts, and other non-peer reviewed scientific correspondence were excluded from retrieval. The results of the independent searches were compared and collated in Excel (Microsoft, Redmond, WA, USA) to eliminate duplicate records. The full texts of records identified as potentially containing relevant data and variables were retrieved and assessed for inclusion.

2.2. Study Selection and Eligibility Criteria

If necessary, retrieved publications were translated using the translation tool in Adobe Acrobat (Adobe San Jose, CA, USA) or Google Translate (Google Mountain View, CA, USA) to facilitate eligibility review and data extraction. Retrieved studies were required to meet the following criteria to be eligible for inclusion: (i) the study utilized larval Cx. pipiens complex (pipiens, quinquefasciatus, or pallens), Ae. Aegypti, or Ae. albopictus laboratory colonies that were regarded by the authors to be a pesticide-susceptible control colony and maintained as such (no publications with F1 susceptible progeny), (ii) late-instar larval mosquitoes were exposed to methoprene or pyriproxyfen over a range of concentrations to develop mortality percentages in a bioassay experiment that included untreated controls, (iii) publications utilized a continuous exposure (exposure of larvae for ≥24 h) methodology that recorded mortality until all mosquitoes were dead or had emerged successfully, (iv) inhibition of emergence (IE) percentages for various exposures were corrected for control mortality and were analyzed using a probit-based methodology to calculate and report original IE50, IE90, and/or IE95 values. These criteria were constructed to include studies that are aligned with WHO IGR larval resistance testing protocols [17,18]. In addition, a publication was excluded if (i) it contained unoriginal reference IE values reprinted and/or cited from previous publications, or (ii) the control/reference mosquitoes were regarded as a pesticide-susceptible reference strain but were identified as F1 progeny or other field-collected mosquitoes.

2.3. Risk of Bias Evaluation

To assess the risk of bias, we evaluated study-level, outcome-level, and publication-level factors. Since our study aims to characterize the variability in published susceptible reference IE values derived from WHO-standardized IGR testing protocols, we designed our eligibility criteria to minimize study-level bias. We excluded publications with clear sources of variation, such as differences in bioassay design, exposure duration, assay length, and reference strain provenance. This approach ensured our study population closely aligned with WHO methodologies while also isolating experimental heterogeneity, biological variation, and other unknown confounders as the primary remaining sources of bias for characterization in this meta-analysis. Because all reported reference IE values were originally intended as experimental controls, the risk of reporting bias was considered negligible. This methodology enabled a synthesis of reference IE values under comparable experimental conditions, facilitated an analysis of heterogeneity within established protocols, and provided a clearer understanding of true susceptibility variation in mosquito populations to IGRs while minimizing known biases.
At the outcome-level, we evaluated the consistency of bioassay and probit regression methods for determining IE50, IE90, and IE95 values. To address redundancy bias from repetitive IE values in the literature, we excluded publications that reported unoriginal or previously published IE values. To reduce the risk of repeated measure bias, publications with multiple measurements on the same reference strain in the same publication were averaged to produce one set of reference values per publication. Publication bias was evaluated subjectively through funnel plots and objectively using Egger’s regression (Supplemental Figures S13–S15) [24].
Included publications were grouped by species and IGR into six distinct subgroups. Each IE value (IE50, IE90, and IE95) for each species/IGR pair was analyzed separately for a total of 18 analyses (3 species × 2 IGRs × 3 IE values). Because Cx. pipiens is a pan-global species complex composed of a variety of subspecies, forms, and hybrids, studies on Culex spp. were first grouped by subspecies to facilitate a subgroup analysis of Cx. quinquefasciatus, pipiens, and pallens to determine if treating the species complex as a single species was appropriate.

2.4. Data Extraction and Formatting

Both authors independently reviewed the retrieved records against the inclusion and exclusion criteria. M.C. extracted the data from the studies identified for inclusion. K.L. audited the data extraction process by comparing data records with the original publications. Any discrepancies were resolved through thorough discussion. No automation tools were used. Publications that met inclusion criteria were grouped by species/IGR pair for data extraction. The following data were extracted from eligible publications:
(1)
Bibliographical information: author names, publication year, journal of publication, etc.
(2)
Subject: mosquito species and subspecies, if applicable (for Culex spp.).
(3)
Intervention: methoprene or pyriproxyfen exposure to larval mosquitoes in a dose/concentration-response bioassay including corrected mortality and probit regression.
(4)
Outcomes: inhibition of emergence concentration point values (IE50, IE90, and/or IE95 values) as well as any uncertainty estimates, if available (95% CI, SD, SE, etc.).
All inhibition of emergence reference values were converted from their published units (ppb, µg/L, mg/L, etc.) to parts-per-million (ppm ±95% CI) and then Log10 transformed to stabilize variance prior to statistical analysis. We chose ppm to maintain consistency across studies and facilitate comparisons, as it is commonly used in larvicide efficacy research. While WHO guidelines often use µg/L, ppm is functionally equivalent (1 ppm = 1 mg/L = 1000 µg/L) and allows for uniformity in our meta-analysis without altering result interpretation. Confidence intervals extracted from the literature were also transformed into Log10 and used to estimate the SD for each IE value. When reported, SE was converted to SD. For publications that lacked reported uncertainty measurements (CI, SD, or SE), the SD was imputed by multiplying the Log10(SD) to Log10(IE) ratio for complete studies by the Log10(IE) value of incomplete studies (those studies requiring an approximated SD) following the method outlined in [25]. Imputed SDs were used for all further analyses for studies that did not include them.

2.5. Statistical and Sensitivity Analyses

The conversion of concentrations, Log10 transformations of data, and imputation of standard deviations (SDs) were performed using Microsoft Excel (Microsoft Inc., Redmond, WA, USA). Statistical analyses, including publication bias assessments (funnel plot and Egger’s regression), heterogeneity assessments, and sensitivity analyses, were conducted using the Meta-Essentials: Excel Workbooks for Meta-analysis tool [26].
The Cx. pipiens complex mosquitoes (quinquefasciatus, pipiens, and pallens) were analyzed in Meta-Essentials using an Analysis of Variance (ANOVA) test to determine if these subspecies groups were significantly different or if they could be treated as a single group for the purposes of computing an overall effect size. Heterogeneity was evaluated both within and across publications using Cochran’s Q, I2, T2, and T for all subgroups with more than 3 publications (16 out of 18 species/IGR/IE pairings). Descriptive statistics (minimum, maximum, interquartile range, median, and geometric mean with ± 95% confidence intervals) for each species/IGR/IE value pairing were generated using GraphPad Prism version 10 (GraphPad Software, Boston, MA, USA). Extracted data (IEconc ± 95% CI) for each species/IGR/IE value pairing were made into a forest plot (Supplemental Figures S1–S6).
The overall effect size (composite IE values) for each subgroup/IGR pair/IE value was determined using a random-effects model in the Meta-Essentials Excel Workbook. This method calculates a combined effect size using inverse variance weighting and incorporates between-study variance through the DerSimonian–Laird (DL) estimator [26,27]. Ninety-five percentile confidence intervals for the DL combined effect values were calculated using a weighted variance methodology [28,29]. The DL combined effect value was calculated for each species (Cx. pipiens complex, Ae. aegypti, and Ae. albopictus), each reference IE value (IE50, IE90, and IE95), and each IGR (methoprene or pyriproxyfen), resulting in a total of 18 DL combined effect IE values with corresponding 95% confidence intervals.
To assess the robustness of the DL combined effect susceptible reference values, three sensitivity analyses were performed: (1) A ROUT outlier test [30] was applied to all species/IGR/IE pairings on log10 transformed values, using a Q value corresponding to a 1% false discovery rate. Identified outliers were removed, and the DL combined effect value was recalculated to assess their influence. (2) To evaluate potential systematic bias from studies requiring imputed confidence intervals, a second sensitivity analysis was conducted by excluding all values from such studies and recalculating the DL combined effect value. (3) The individual weights of each study used for the DL method were calculated and qualitatively assessed for homogeneity. (4) A geometric mean with 95% CIs was calculated for each species/IGR/IE value to compare against the DL inverse variance weighting methodology, providing an alternative measure of central tendency.
All DL combined effect values (n = 18) were assessed for certainty using a modified GRADE approach [31]. Risk of bias and indirectness were considered minimal for each subgroup since all included studies followed WHO protocols, and this meta-analysis focuses exclusively on control values from previous literature. DL combined effect values were downgraded if they exhibited high heterogeneity (I2 > 75%) and/or if their upper 95% confidence interval exceeded three times the DL combined effect value. If Egger’s regression indicated publication bias within a subgroup pairing, the certainty of the DL combined effect value was downgraded by one level accordingly. In the final analysis, the DL combined effect susceptible values were compared to the original published IE values to calculate a resistance ratio (published IE50 value/DL combined effect IE50 value). This analysis aims to identify the number and percentage of publications that may have inadvertently used potentially resistant mosquitoes as susceptible references.

3. Results

3.1. Literature Search and Study Selection Results

Our search strategy identified 1421 records across the four databases (401 from PubMed, 193 from J-STAGE, 24 from SciELO, and 803 from Google Scholar; Figure 1) for our six species/IGR pairings. After the titles and abstracts were reviewed for duplicate records, 241 reports were sought for retrieval. Of the 241 reports sought for retrieval, 26 studies contained data on multiple species or IGRs and were only retrieved once, yielding a total of 215 unique publications. An assessment for eligibility concluded that 84 were excluded for lacking a probit-based analysis of the mortality results, a further 10 were excluded for lacking IE value data on the species of interest, 26 were excluded for the use of a reference strain that did not meet inclusion criteria, 20 were excluded for not utilizing a continuous immersion design and, finally, 3 were excluded for reporting IE values from a previous publication. This yielded a total of 98 records from 72 unique publications that were eligible for inclusion (Figure 1). A total of 24 studies were identified that contained data for the Cx. pipiens/methoprene pairing [9,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54], 17 for Ae. aegypti/methoprene [37,38,39,40,52,55,56,57,58,59,60,61,62,63,64,65], 8 for Ae. albopictus/methoprene [40,42,49,60,66,67,68,69], 12 for Cx. pipiens/pyriproxyfen [34,40,50,65,70,71,72,73,74,75,76,77], 26 for Ae. aegypti/pyriproxyfen [37,40,56,57,64,65,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96] and, finally, 11 for Ae. albopictus/pyriproxyfen [40,66,68,69,89,90,97,98,99,100,101]. A forest plot of extracted IE values, as well as their associated confidence intervals (if reported) can be found in Supplemental Figures S1–S6 for all species/IGR/IE pairings.

3.2. Risk of Bias, Culex spp. Subgroup, and Heterogeneity Analysis Results

Since the inclusion criteria closely followed the WHO IGR larvicide test protocol and ensured that only studies meeting at least the minimum standards were included, and because the exclusion criteria were designed to isolate study-level and outcome-level bias from variability inherent in the protocol design, no additional exclusions of publications for bias were deemed necessary. An ANOVA subgroup analysis of Cx. pipiens, quinquefasciatus, and pallens indicated that there was no significant difference between these subgroups for either methoprene at IE50, IE90, or IE95, or pyriproxyfen at IE50 and IE90 (Table 1). As no significant differences in IE values were found for these species’ subgroups, the three Culex subspecies were treated as a single group for all subsequent analyses.
As demonstrated in Table 2, there was significant heterogeneity between studies. The I2 values for each published IE value ranged from 34.09% to 99.84% with 16 out of 18 subgroups exhibiting values above 75%, indicating that most of the heterogeneity resulted from differences between studies rather than from the variability found within studies. The pooled estimates (T) were found to range from 0.13 to 1.76, indicating that the true effect sizes across studies (10T) varied by a factor of between 1.34- and 57.97-fold (Table 2).
Funnel plots and an Egger’s regression were used to assess potential publication bias for each species/IGR/IE value pairing. As Table 3 demonstrates, only the Ae. albopictus/methoprene/IE50 exhibited a p-value < 0.05 (p = 0.043), indicating asymmetry in the funnel plot (Supplemental Figures S13–S15). The Cx. pipiens/pyriproxyfen/IE90 subgroup exhibited a p-value of 0.055, indicating a marginal asymmetry in the funnel plot (Figure S13E). The remaining subgroup pairings either did not have enough publications for us to conduct the regression (n = 2), or were not significant (n = 14).

3.3. Summary Statistics, Combined Effects Sizes, and Sensitivity Analysis

The summary statistics for all species/IGR/IE combinations are presented in Table 4 (reported in ppb). As expected, the minimum, interquartile range (IQR), median, and maximum IE values increase from IE50 to IE90 across all species/IGR pairings. However, some species/IGR pairings demonstrate a decrease in concentration from IE90 to IE95. The DL combined effect value demonstrates that, for all species, pyriproxyfen is active at approximately a 10-fold lower concentration than methoprene at the IE50 value. In addition, the DL combined effect value for Ae. albopictus at IE50 demonstrates that this species is less sensitive to the IGRs examined in this study than either Cx. pipiens or Ae. aegypti (Table 4). Figure 2 illustrates the distribution of extracted IE values (open circle) as well as the DL combined effect value (red circle). In nearly all species/IGR/IE pairings, the DL combined effect value clustered towards the center of the distribution of published IE values. Also notable is that, in four out of six IE95 pairings, the DL combined effect value declined from the IE90 value.
Table 5 contains the results of three of the sensitivity analyses that were conducted. Most comparisons between the various analyses indicated little effect from studies that did not report confidence intervals or from studies that could be identified as outliers. In nearly all cases where a sensitivity analysis could be conducted, the combined effect size remained robust. However, in the Ae. aegypti/methoprene/IE90 pairing, the removal of two outliers doubled the DL combined effect value (from 4.559 ppb to 9.208 ppb), indicating that two studies were strongly influencing and lowering this IE90 value. In addition, the geometric means and 95% confidence interval for all species/IGR/IE pairings agreed well with those derived using the DL method. Supplemental Figures S7–S12 display the weighting of each publication within the DL method to create an overall combined effect size for each subgroup pairing. As these figures illustrate, there were no publications that exhibited an excessive weighting or influence on the DL combined effect value (Supplemental Figures S7–S12).
A certainty of evidence analysis was conducted for all species/IGR/IE value pairings (Table 6). The DL combined effect IE50 and IE90 values for methoprene were evaluated to be moderately certain for Cx. pipiens and Ae. aegypti and low to very low for Ae. albopictus. For pyriproxyfen, the IE50 value was again evaluated to be moderate for Cx. pipiens and Ae. aegypti and low for Ae. albopictus. The most common factor that caused a downgrade in the certainty was the high heterogeneity observed across studies, followed by imprecision (upper 95% confidence intervals more than 3× the DL combined effect value) (Table 6). One subgroup was downgraded for possible publication bias (Ae. albopictus/methoprene/IE50), and another exhibited marginal publication bias but was not downgraded (p-value = 0.055; Cx. pipiens/pyriproxyfen/IE90). In two cases, there were not enough publications to conduct an Egger’s regression nor enough publications to assess inconsistency (Ae. aegypti/methoprene/IE95 and Ae. albopictus/methoprene/IE95), and so these subgroups were similarly downgraded on both of these criteria (Table 7).
To assess how assumptions of susceptibility in the reviewed literature compare with the DL combined effect values from our meta-analysis, we calculated resistance ratios (RRs) using our DL combined effect value as a reference value. For Ae. albopictus, a comparison of our methoprene DL combined effect IE50 value against the original published susceptible reference values showed that 25% (two out of eight) of reference strains exhibited an RR > 5 (Table 7). For pyriproxyfen, 18% (2 out of 11) studies exhibited RRs > 10, indicating the presence of resistance in supposedly susceptible reference mosquitoes, while the remaining RRs were <5 (Table 7). For Ae. aegypti, the methoprene comparisons showed that 11.7% (2 out of 17) of reference strains had RRs > 5, with another 47% (8 out of 17) between 1 and 5 (Table 4). For pyriproxyfen, 12% (6 out of 26) studies exhibited RRs between 1 and 5, with another three exceeding RR 10 (Table 7). For Cx. pipiens, the methoprene pair showed only 8% (2 out of 24) studies with RRs >5, while the pyriproxyfen pair showed 8% (1 out of 12) with RRs > 5 (Table 7).

4. Discussion

4.1. Literature Characterization

In this review and meta-analysis, we systematically collected publications containing inhibition of emergence value data on reference vector mosquitoes that were considered susceptible by the study authors (summarized in Supplemental Figures S1–S6). To the best of our knowledge, this is the first comprehensive review and analysis of published reference values for the IGRs methoprene and pyriproxyfen. Reference IE values form the basis for nearly all dose/concentration-response mosquito resistance assessments, significantly influencing product selection, product rotation strategies, and broader mosquito management and public health decisions [18]. Therefore, characterizing and summarizing these reference values provides critical context for interpreting both historical and future reports of resistance in vector mosquitoes. From this meta-analysis, we identified several key findings: (1) Despite using eligibility criteria designed to exclude major sources of bias, the remaining literature still demonstrates a strikingly high degree of heterogeneity between studies. (2) Many experimental controls and design elements outlined in WHO and other standardized protocols may not be sufficient to ensure reliable resistance measurements across studies. (3) Some reference populations labeled as susceptible may not be truly susceptible. Consequently, resistance in field populations could go unnoticed, as inflated reference values may underestimate resistance ratios. (4) Finally, we provide DL combined effect IE50, IE90, and IE95 values for two IGRs and three mosquito species that can be used for future resistance evaluations, should a susceptible reference colony be inaccessible.
Heterogeneity in the published IE values, as characterized by I2 indices (Table 2), was consistently high—exceeding 75% in nearly all species/IGR/IE pairings where this metric could be calculated. This suggests that most variation in the dataset arises from differences between studies rather than within-study variability. The WHO protocol for larval resistance testing recommends conducting bioassays in triplicate, with untreated controls to correct mortality before fitting a probit regression. This level of replication and internal control within each study helps minimize within-study variability, improve probit regression accuracy, and narrow confidence intervals. However, while reducing within-study variability enhances precision, it can also amplify heterogeneity estimates that assess variability between studies; especially when unknown confounders or methodological discrepancies may exist.
Funnel plots and Egger’s regression are used to assess the relationship between effect size (in this case, logged IE value) and standard error. Completely unbiased literature based on the same sample population will produce results that vary randomly around the true effect size, creating a symmetrical funnel plot and a non-significant Egger’s regression. Selective reporting of results (publication bias) and/or the assessment of biologically different populations will produce a plot with systematic asymmetry. However, in this meta-analysis, we analyzed the controls (rather than the treatment effect) that were used as a baseline, mainly for observational studies. Because we are analyzing the baseline controls, the risk of publication bias and selective reporting with this type of data is implicitly lower. Only one subgroup pairing, Ae. albopictus/methoprene/IE50, demonstrated a significant p-value indictive of asymmetry (Table 3; p = 0.043). The Cx. pipiens/pyriproxyfen/IE90 pairing also exhibited a marginal asymmetry (Table 3; p = 0.055). These results suggest that the IE reference values analyzed in this meta-analysis are assessing distinct biological populations of Ae. albopictus rather than estimates of a single underlying effect and, thus, the asymmetry in the funnel plot may reflect true biological variability in reference colonies rather than publication bias. Additionally, the high heterogeneity observed in the dataset suggests that differences in mosquito strain susceptibility, rearing conditions, or testing methodologies is contributing to the observed asymmetry.
Although most studies measured their reference populations with high precision, variations in methodology, biological factors, and other unknown factors contributed to the high heterogeneity observed in IE values (Table 2). This heterogeneity persisted despite general adherence to WHO protocols, which are designed to enhance the accuracy and precision of IGR resistance testing. However, methodological differences—such as variations in larval rearing conditions, exposure durations, and test environments—may have influenced the observed variability. The certainty analysis of the DL combined effect values indicated that high heterogeneity led to a downgrade in the certainty of our values in 16 out of 18 subgroups (Table 7). Additionally, limited publication data reduced certainty in the Ae. aegypti/methoprene/IE95 and Ae. albopictus/methoprene/IE95 pairings. A lack of precision, defined as 95% confidence intervals exceeding three times the DL combined effect value, was observed in 10 out of 18 pairings. Overall, both Cx. pipiens and Ae. aegypti exhibited moderately certain DL combined effect values for IE50 and IE90. In contrast, the relative scarcity of studies on Ae. albopictus, coupled with high heterogeneity, resulted in low certainty estimates across most concentrations and IGRs. The outcome observed here highlights an urgent need for greater standardization in experimental design and more rigorous reporting of experimental conditions to improve cross-study comparisons.

4.2. Standardized Protocols and Methodological Variability

The WHO’s standardized IGR testing protocols, outlined in a series of publications [17,18], modify standard toxicity bioassays by replacing lethal dose (LD) or lethal concentration (LC) measurements with inhibition of emergence (IE50, IE90, and IE95) values, given the unique action of juvenoid IGRs. To properly apply a probit-based methodology to IGRs, several key adjustments and controls must be incorporated [17]. Since juvenoid IGRs disrupt metamorphosis rather than cause immediate toxicity, bioassays must monitor larvae until either successful emergence or death. During this period, larvae should be fed. WHO recommendations include finely ground yeast extract, rabbit pellets, or ground fish/mouse food [17]. Other standardized conditions include the use of untreated controls with mortality correction, use of either technical grade or formulated IGR stock solutions, environmental controls (a temperature of 25–28 °C and a 12 L:12 D photoperiod), use of disposable cups, glass bowls, or beakers for assays, and reference populations derived from either laboratory colonies or susceptible F1 progeny from field-collected mosquitoes [18]. Our inclusion criteria closely aligned with all WHO recommendations, allowing protocol variability, but deliberately excluded studies conducted with F1 progeny of field-collected mosquitoes.
Despite these standardized protocols, some of the observed interstudy variation likely stems from experimental details such as feeding regime, bioassay container material, temperature, and IGR source. For instance, pyriproxyfen is well adsorbed by organic materials, making it more likely to be ingested by larvae [97,102]. This suggests that the timing, method, and type of food used could influence both the bioavailability of the IGR and the amount ingested by larvae. In addition, bioassay container material significantly affects pyriproxyfen IE values, with variations of up to 150-fold across different materials (glass, concrete, rubber, polystyrene, etc.) [100]. Methoprene is similarly known to exhibit hydrophobic binding tendencies and would be expected to be vulnerable to the same biases [103]. Additionally, WHO protocols permit the use of both technical grade and formulated products, but formulated products can often include unreported solubility-enhancing agents or other adjuvants, potentially making their bioavailability difficult to compare with technical grade materials [104]. Both methoprene and pyriproxyfen are poorly soluble in water, and WHO recommendations suggest the use of either ethanol or acetone as a diluent (based on manufacturer recommendation) [17,105]. Both diluents are toxic to mosquitoes in higher concentrations, necessitating the dosing of small quantities of diluted active ingredients, further complicating bioassay standardization [17].
Although WHO protocols attempt to control temperature and photoperiod, both of which can influence the effects and degradation of IGRs [48,106,107], minor variations in these parameters may still be introducing significant sources of heterogeneity. We did not attempt to subgroup and analyze studies based on these factors because some experimental conditions were inconsistently reported in the literature, precluding further subgroup analysis, and much of the variability in experimental conditions is explicitly allowed under WHO protocols. Each of the aforementioned factors may be exhibiting an effect on the determination of susceptible IE values, which may not matter much within a well-controlled study but may hinder interstudy comparisons or the identification of regional trends or patterns.

4.3. Biological Variability in Reference Strains

While minor methodological differences may exist across studies, the most likely source of between-study variability is the inherent biological differences in reference mosquito strains. Even after excluding studies using the progeny of recently field-collected mosquitoes (F1) with an unknown susceptibility status, high variability persisted (Table 2). A qualitative review of eligible studies reveals that reference strains originated from commercial suppliers, universities, mosquito control districts, government laboratories, and other entities. Some susceptible strains have been laboratory-maintained for decades (e.g., Rockefeller strain, Ae. aegypti), while others were recently colonized following global invasions and likely experienced exposure to pesticides or other chemistries prior to captivity (e.g., ATM95, Ae. albopictus). In some cases, strains were generically labeled as “pesticide-susceptible” or assigned conflicting or unclear names (e.g., SLAB vs. University of Montpellier), making it difficult to determine their provenance. In addition, the literature used in this meta-analysis was derived primarily from the United States, Japan, and, to a lesser degree, Southeast Asia, the Caribbean, and South America. It is unknown what effect this geographic clustering of the primary literature may be exhibiting on the various parameters assessed in this meta-analysis.
Since Culex subspecies were clearly described in all included publications, we evaluated whether subspecies-level variation could explain the observed heterogeneity, at least for Cx. pipiens complex IE values. We sub-grouped the Cx. pipiens species complex (pipiens, quinquefasciatus, and pallens), and there were no significant differences between subspecies groups (Table 1). Moreover, in all comparisons, the F-statistic was <1, indicating that within-subspecies-group variance exceeded between-subspecies-group variance (Table 1). This result suggests that the source of reference Culex spp. mosquitoes was more important than their taxonomic designation and highlights how biological variation within reference colonies may be an underappreciated confounding factor in resistance assessments. A similar analysis of the potential of biological variability to be the cause of high heterogeneity for Ae. aegypti and Ae. albopictus was not conducted due to a lack of consistent information that could enable a subgroup comparison. However, the high heterogeneity observed for these species (Table 2) indicates that variability—either biological or methodological—exists.
A comparison of Cx. pipiens and Ae. aegypti DL combined effect IE50 values for methoprene and pyriproxyfen shows remarkable similarity (0.428 ppb vs. 0.505 ppb for methoprene and 0.048 ppb vs. 0.053 ppb for pyriproxyfen; Table 3 and Table 4). However, Ae. albopictus exhibited DL combined effect IE50 values that were approximately threefold higher than those of Cx. pipiens and Ae. aegypti (Table 3). Notably, over 60% of studies on Ae. albopictus/methoprene and over 90% on Ae. albopictus/pyriproxyfen were published after the year 2000, by which time this species had already invaded most continents [108,109]. This suggests that the relatively recent global invasion of Ae. albopictus may have resulted in laboratory colonies being established from source populations that were less susceptible than originally assumed. Alternatively, it is possible that Ae. albopictus exhibits some undescribed constitutive features that result in lower susceptibility to IGRs. In addition, there were comparatively fewer studies that examined Ae. albopictus, which may contribute to these differences and reduce the robustness of our DL combined effect values for this species. Future resistance assays with Ae. albopictus should pay closer attention to the generated susceptible reference values, as seemingly small increases in susceptible reference value can have disproportionate effects on the resultant RR, thus obscuring detections of resistance.
As Table 5 shows, there are a variety of publications where the susceptible reference strains should be regarded as “moderately resistant” or “highly resistant” under WHO criteria (RR 5–10 or RR > 10) when compared to the susceptible DL combined effect value we generated in the meta-analysis [18]. In the most extreme examples, the Ae. albopictus/pyriproxyfen pair resulted in two publications with an RR > 200. In the Ae. aegypti/pyriproxyfen pair, two studies exceeded an RR of 20. It is important to note that, since susceptible reference values form the denominator in the resistance ratio calculation, any increase in this denominator results in a non-linear inverse (hyperbolic) decrease in RR, potentially obscuring resistance detection. Therefore, published reference values that exceed our DL combined effect value by a ratio of between 1 and 5, which seems moderate, are still considered “susceptible” under WHO definitions and may disproportionately and dramatically skew RR calculations lower, potentially underestimating resistance.
Together, the results presented in Table 5 strongly suggest that laboratory strains of Ae. aegypti and Ae. albopictus (and, to a lesser degree, Cx. pipiens) should not be assumed to be susceptible, despite a presumed lack of pesticide exposure or an unbroken laboratory lineage. Given the stenogamous nature of Aedes spp. mosquitoes, inadvertent admixture between lab and field strains in insectaries may have also contributed to the variability observed in these colonies. Alternatively, pesticide exposure prior to colony establishment, cross-resistance between pesticide or chemical classes, or unintended pesticide exposures within laboratories may be more common than previously recognized. Finally, it is possible that founder effects or genetic bottlenecking have isolated reference strains from each other, making cross-study comparisons much more difficult. Future resistance assessments should strongly consider alternative methods to verify the susceptibility of their reference strains—either by comparing them to the values generated here or through independent validation methods.

4.4. Combined Effect Values

One goal of this meta-analysis is to integrate data from multiple bioassays to establish a more robust benchmark for future resistance evaluations. Table 3 presents summary statistics and the DL combined effect IE values with 95% confidence intervals. Due to high between-study variability and low within-study variability, the weights assigned to individual studies in the DL model were overall very similar between studies (Supplemental Figures S4–S6). There were no studies that exerted a disproportionate weight on the DL combined effect value. The sensitivity analyses conducted indicate that neither studies requiring imputation of confidence intervals, nor those with outliers removed, exerted much of an effect on the DL combined effect values, except for the Ae. aegypti/methoprene/IE90 pairing, where two values identified as outliers were exerting a large effect on the resulting DL combined effect value (Table 4). When taken together, these results indicate that, for most species/IGR/IE pairings, we were able to generate moderately robust susceptible reference values for use as a comparison or to validate other reference values.
With all studies analyzed together, the DL combined effect values for IE50, IE90, and IE95 tended to fall around the center of the distribution of values extracted from the literature and were remarkably similar to the geometric mean (Figure 2). A comparison between the geometric mean and DL combined effect value also demonstrates that within-study variation had minimal influence on the DL combined effect values (Table 4). Given that both our DL combined effect value and geometric mean values are well-centered within a wide range of original values, and that small increases in the IE reference values can disproportionately decrease the resulting RR when assessing resistance, the DL combined effect and/or geometric mean values likely represent the upper bound of what should be considered truly susceptible reference mosquitoes. In addition, the lack of sensitivity of the DL combined effect values to outliers and other potential biases suggests that the values generated here, especially at IE50, are reasonable estimates that can be used to compare against a wide range of experimental conditions.
The summaries presented in Table 3 represent a composite of all published IE values and can serve multiple purposes: (1) assessing the continued susceptibility of existing reference strains, (2) assessing the susceptibility of F1 field-collected strains intended for use as references, and (3) providing a potential benchmark to accompany WHO larval IGR resistance protocols. However, since the source values used to derive composite values (geometric mean or DL combined effect) vary by orders of magnitude, these statistics should always be interpreted alongside their 95% confidence intervals when calculating resistance ratios. In other words, any resistance ratios derived from composite values in Table 3 or Table 4 should be reported as a range that includes both the lower and upper confidence limits rather than as a point estimate.
Though we report composite DL combined effect IE90 and IE95 values, the number of studies that reported these values was extremely limited, resulting in less robust estimates that suffered from inconsistency and imprecision and were downgraded accordingly (Table 6). In addition, IE90 and IE95 values are derived from the extreme end of the probit curve, making them more susceptible to heterogeneity in the sampled population compared to IE50 values. As a result, these higher IE values exhibit a wider distribution in the literature, which in turn lowers the certainty of the DL combined effect as assessed in Table 6. Table 3 indicates that IE95 values frequently decreased from IE90 values, contrary to the usual expectation of an increase, in part due to a lack of included values. Indeed, caution should be exercised in interpreting IE95 values for all pairings except for Ae. aegypti/pyriproxyfen. Various other species/IGR/IE pairings also exhibit “low” or “very low” certainty (Table 6). This suggests that, while a DL combined effect was computable, the addition of new evidence would likely have a noticeable impact on this value. In contrast, IE values assessed as “moderately” certain are less likely to be influenced by new evidence. In any case, all DL combined effect values have been reported with confidence intervals (with low-certainty estimates necessarily having wider confidence intervals) and should be regarded as a range rather than a point estimate to account for differences in the certainty of the estimate.
In place of comparing to the DL combined effect IE90 and IE95 values, summary statistics such as medians and the IQR could also be used for assessment. Inclusion of IE90 values, as recommended by the WHO, is necessary in future susceptibility evaluations. A large gap between IE50 and IE90 values can be indicative of resistance in a small portion of the population. In the case of maintaining susceptible mosquito colonies, this is a critical piece of evidence for potential accidental exposure to insecticides or underlying residual resistance after field colonization.

4.5. Statistical Considerations

Probit regression remains the standard toxicological method for quantifying susceptibility and resistance to pesticides, as it captures the non-linear dose/concentration-response relationship inherent in bioassays [110,111]. However, there are statistical considerations and interpretations that are often ignored. Although our inclusion criteria for this meta-analysis included the use of a probit analysis methodology for calculating IE values, we did not evaluate model fit nor require the inclusion of confidence intervals. Without including a statistical test to demonstrate the fit of the data, it is possible that the bioassay data used do not fit a probit distribution, leading to incorrect IE values and wider confidence intervals. The most common ways to evaluate regression fit are Pearson’s χ2 goodness-of-fit test, an alternative χ2 test, or evaluating the H value (χ2/df). The potential for poorly fitted probit regressions may be an additional level of variability within this meta-analysis. Furthermore, comparing confidence intervals can be used in place of or in addition to calculating a resistance ratio for interpreting susceptibility differences between populations. A ratio test can be used to determine if the results from two probit analyses are significantly different, rather than just reporting the fold change in IE values [112]. These additional statistical elements, recommended by the WHO [18], need to be reported in future studies.
We acknowledge that some of the studies included were conducted before the availability of modern computing equipment or performed on log-probit paper; thus, calculating confidence intervals and model fit was too cumbersome or inaccessible. However, with modern statistical software, probit analyses complete with confidence intervals and fit assessment should be the standard. R studio, Microsoft Excel, SPSS, Polo, Python, and SAS are commonly used statistical programs or languages that provide these outputs, some of which are completely free to download and use.

4.6. Recommendations and Future Directions

Resistance monitoring in vector mosquitoes is a critical component of effective mosquito management, and WHO protocols provide an indispensable framework for conducting standardized resistance assessments. However, uncharacterized confounders—such as experimental differences and inherent biological variations in colony populations—can obscure resistance patterns and complicate cross-study comparisons. Without reliable assessments or clear study-to-study comparisons, identifying trends in resistance becomes challenging, ultimately impacting the ability of public health and vector control agencies to manage mosquito populations effectively.
The goal of this review and meta-analysis was to better understand the variability in reported IE values and to establish benchmark values that help researchers assess the reliability of their findings. Additionally, this study aimed to highlight potential shortcomings in current experimental methods that may contribute to inconsistent results. Based on our findings, several recommendations can be made:
  • Existing protocols should be more detailed. For example, the use of disposable bioassay containers (such as polystyrene cups) should be universally recommended, along with a standardized larval feeding regime. Any experimental conditions left open to interpretation should be reevaluated and defined as precisely as possible.
  • Reference colonies should be periodically assessed for continued susceptibility, either through comparisons with other reference colonies or against the benchmark values reported here. No assumptions about susceptibility or pesticide exposure should be made.
  • The source of reference mosquitoes and any ongoing susceptibility assessments should be more thoroughly documented in the literature.
  • If F1 progeny of field-collected mosquitoes (or other field-collected mosquitoes) will be used as susceptible references, then they should be compared against the benchmarks generated here to assess the applicability of these reference values prior to any resistance determinations.
  • All bioassay probit analyses should report IE50, IE90, a goodness-of-fit evaluation, and confidence intervals for each mosquito population evaluated.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/tropicalmed10040087/s1, Figures S1–S6: Forest plots of species/IGR values reported in the literature. Figures S7–S12: Weighting of each study at IE50, IE90, and IE95. Figures S13–S15: Funnel plots of published IE values.

Author Contributions

Conceptualization: M.E.C. and K.L.; methodology, M.E.C. and K.L.; software, M.E.C.; validation, K.L.; formal analysis, M.E.C.; investigation, M.E.C. and K.L.; resources, M.E.C. and K.L.; data curation, M.E.C. and K.L.; writing—original draft preparation, M.E.C.; writing—review and editing, M.E.C. and K.L.; visualization, M.E.C.; supervision, M.E.C.; project administration, M.E.C. All authors have read and agreed to the published version of the manuscript.

Funding

The North Shore Mosquito Abatement District is a taxpayer-funded special district and supported this research. This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data extracted from included studies is available upon reasonable request. Data used for all analyses is available upon reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest or competing interests.

Abbreviations

The following abbreviations are used in this manuscript:
ANOVAAnalysis of Variance
CIConfidence interval
DLDerSimonian and Laird
IE Inhibition of emergence
IGRInsect growth regulator
IQRInterquartile range
SD Standard deviation
SE Standard error
RR Resistance ratio
WHOWorld Health Organization.

References

  1. Kilpatrick, A.M.; Randolph, S.E. Drivers, dynamics, and control of emerging vector-borne zoonotic diseases. Lancet 2012, 380, 1946–1955. [Google Scholar] [CrossRef] [PubMed]
  2. Beard, C.B.; Visser, S.N.; Petersen, L.R. The need for a national strategy to address vector-borne disease threats in the United States. J. Med. Entomol. 2019, 56, 1199–1203. [Google Scholar] [CrossRef] [PubMed]
  3. de Souza, W.M.; Weaver, S.C. Effects of climate change and human activities on vector-borne diseases. Nat. Rev. Microbiol. 2024, 22, 476–491. [Google Scholar] [CrossRef]
  4. Patterson, G. The Mosquito Crusades: A History of the American Anti-Mosquito Movement from the Reed Commission to the First Earth Day; Rutgers University Press: New Brunswick, NJ, USA, 2009. [Google Scholar]
  5. Becker, N.; Petric, D.; Zgomba, M.; Boase, C.; Madon, M.; Dahl, C.; Kaiser, A. Mosquitos and Their Control, 2nd ed.; Springer: Heidelberg, Germany, 2010; pp. 441–476. [Google Scholar]
  6. Floore, T.G. Mosquito Larval Control Practices: Past and Present. J. Am. Mosq. Control Assoc. 2006, 22, 527–533. [Google Scholar] [CrossRef]
  7. Su, T. Resistance and Its Management to Microbial and Insect Growth Regulator Larvicides in Mosquitoes. In Insecticide Resistance; Trdan, S., Ed.; InTechOpen: London, UK, 2016; pp. 135–154. [Google Scholar] [CrossRef]
  8. Su, R. Resistance and resistance management of biorational larvicides for mosquito control. J. Florida Mosq. Control Assoc. 2022, 69, 9–15. [Google Scholar] [CrossRef]
  9. Su, T.; Cheng, M.L. Laboratory selection of resistance to spinosad in Culex quinquefasciatus (Diptera: Culicidae). J. Med. Entomol. 2014, 51, 421–427. [Google Scholar] [CrossRef]
  10. Williams, C.M. Third-Generation Pesticides; Scientific American Magazine: New York, NY, USA, 1967; pp. 13–17. [Google Scholar] [CrossRef]
  11. Oberlander, H.; Silhacek, D.L. Insect Growth Regulators. In Alternatives to Pesticides in Stored-Product IPM; Subramanyam, B., Hagstrum, D.W., Eds.; Springer: New York, NY, USA, 2000; pp. 147–163. [Google Scholar] [CrossRef]
  12. Lawler, S.P. Environmental safety review of methoprene and bacterially-derived pesticides commonly used for sustained mosquito control. Ecotoxicol. Environ. Saf. 2017, 139, 335–343. [Google Scholar] [CrossRef]
  13. World Health Organization (WHO). Review of the insect growth regulator pyriproxyfen. In Report of the 4th WHOPES Working Group Meeting; WHO Press: Geneva, Switzerland, 2000; pp. 50–67. [Google Scholar]
  14. Parthasarathy, R.; Palli, S.R. Stage-specific action of juvenile hormone analogs. J. Pestic. Sci. 2021, 46, 16–22. [Google Scholar] [CrossRef] [PubMed]
  15. Nishiura, J.T.; Ray, K.; Murray, J. Expression of nuclear receptor-transcription factor genes during Aedes aegypti midgut metamorphosis and the effect of methoprene on expression. Insect Biochem. Mol. Biol. 2005, 35, 561–573. [Google Scholar] [CrossRef]
  16. Wu, Y.; Parthasarathy, R.; Bai, H.; Palli, S.R. Mechanisms of midgut remodeling: Juvenile hormone analog methoprene blocks midgut metamorphosis by modulating ecdysone action. Mech. Dev. 2006, 123, 530–547. [Google Scholar] [CrossRef]
  17. World Health Organization (WHO). Guidelines for Laboratory and Field Testing of Mosquito Larvicides; WHO Press: Geneva, Switzerland, 2005; pp. 1–19. [Google Scholar]
  18. World Health Organization (WHO). Monitoring and Managing Insecticide Resistance in Aedes mosquito Populations: Interim Guidance for Entomologists; WHO Press: Geneva, Switzerland, 2016; pp. 1–11. [Google Scholar]
  19. Namias, A.; Jobe, N.B.; Paaijmans, K.P.; Huijben, S. The need for practical insecticide-resistance guidelines to effectively inform mosquito-borne disease control programs. Elife. 2021, 6, e65655. [Google Scholar] [CrossRef]
  20. Richards, S.L.; Byrd, B.D.; Breidenbaugh, M.; Vandock, K. Survey of United States mosquito control programs reveals opportunities to improve the operational value of Centers for Disease Control and Prevention bottle bioassays. J. Med. Entomol. 2022, 59, 1827–1830. [Google Scholar] [CrossRef] [PubMed]
  21. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int. J. Surg. 2010, 8, 336–341. [Google Scholar] [CrossRef] [PubMed]
  22. Haddaway, N.R.; Page, M.J.; Pritchard, C.C.; McGuinness, L.A. PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimized digital transparency and Open Synthesis. Campbell Syst. Rev. 2022, 18, e1230. [Google Scholar] [CrossRef]
  23. Richardson, W.S.; Wilson, M.C.; Nishikawa, J.; Hayward, R.S. The well-built clinical question: A key to evidence-based decisions. ACP J. Club 1995, 123, A12-3. [Google Scholar]
  24. Egger, M.; Smith, G.D.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315, 629–634. [Google Scholar] [CrossRef]
  25. Lajeunesse, M.J.; Koricheva, J.; Gurevitch, J.; Mengersen, K. Recovering missing or partial data from studies: A survey of conversions and imputations for meta-analysis. In Handbook of Meta-Analysis in Ecology and Evolution; Koricheva, J., Gurevitch, J., Mengersen, K., Eds.; Princeton University Press: Princeton, NJ, USA, 2013; pp. 195–206. [Google Scholar]
  26. Suurmond, R.; van Rhee, H.; Hak, T. Introduction, comparison and validation of Meta-Essentials: A free and simple tool for meta-analysis. Res. Synth. Methods 2017, 8, 537–553. [Google Scholar] [CrossRef]
  27. DerSimonian, R.; Laird, N. Meta-analysis in clinical trials. Control Clin. Trials 1986, 7, 177–188. [Google Scholar] [CrossRef]
  28. Sánchez-Meca, J.; Marín-Martínez, F. Confidence intervals for the overall effect size in random-effects meta-analysis. Psychol. Methods 2008, 13, 31–48. [Google Scholar] [CrossRef]
  29. Van Rhee, H.J.; Suurmond, R.; Hak, T. User Manual for Meta-Essentials: Workbooks for Meta-Analysis (Version 1.4); Erasmus Research Institute of Management: Rotterdam, The Netherlands, 2015; Available online: www.erim.eur.nl/research-support/meta-essentials (accessed on 30 January 2025).
  30. Motulsky, H.J.; Brown, R.E. Detecting outliers when fitting data with nonlinear regression–a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinf. 2006, 7, 123. [Google Scholar] [CrossRef]
  31. Schünemann, H.; Brożek, J.; Guyatt, G.; Oxman, A. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. 2013. Available online: https://gdt.gradepro.org/app/handbook/handbook.html (accessed on 2 February 2025).
  32. Navarro, A.; Garcia, F.A.; Valdes, S.; Marquetti, M.D.C. Laboratory evaluation of three insect growth regulators against a malathion resistant strain of Culex quinquefasciatus (Diptera: Culicidae). Mem. Inst. Oswaldo Cruz. 1992, 87, 603–604. [Google Scholar] [CrossRef]
  33. Kamei, M.; Shimada, S.; Asano, S.; Ishii, T. Comparative susceptibility of methoprene and organophosphorus insecticides in Japanese and Chinese populations of Culex pipiens. Jpn. J. Environ. Entomol. Zool. 1992, 4, 30–32. [Google Scholar] [CrossRef]
  34. Su, T.; Thieme, J.; Ocegueda, C.; Ball, M.; Cheng, M.L. Resistance to Lysinibacillus sphaericus and other commonly used pesticides in Culex pipiens (Diptera: Culicidae) from Chico, California. J. Med. Entomol. 2018, 55, 423–428. [Google Scholar] [CrossRef]
  35. Ohsumi, T.; Hatakoshi, M.; Kisida, H.; Matsuo, N.; Nakayama, I.; Itaya, N. Oxime ethers: New potent insect growth regulators. Agric. Biol. Chem. 1985, 49, 3197–3202. [Google Scholar] [CrossRef]
  36. Noguchi, Y.; Ohtaki, T. Difference in the susceptibility of Culex larvae against methoprene and its slow-release formulation A at various stages of development. Jpn. J. Sanit. Zool. 1974, 25, 185–189. [Google Scholar] [CrossRef]
  37. Hatakoshi, M.; Kawada, H.; Nishida, S.; Kisida, H.; Nakayama, I. Laboratory evaluation of 2-[1-methyl-2-(4-phenoxyphenoxy) ethoxy] pyridine against larvae of mosquitoes and housefly. Med. Entomol. Zool. 1987, 38, 271–274. [Google Scholar] [CrossRef]
  38. Hatakoshi, M.; Ohsumi, T.; Kisida, H.; Itaya, N.; Nakayama, I. Mosquito larvicidal activity of juvenile hormone active oxime ether compounds. Med. Entomol. Zool. 1986, 37, 99–104. [Google Scholar] [CrossRef]
  39. Kisida, H.; Hatakoshi, M.; Itaya, N.; Nakayama, I. New insect juvenile hormone mimics: Thiolcarbamates. Agric. Biol. Chem. 1984, 48, 2889–2891. [Google Scholar] [CrossRef]
  40. Pocquet, N.; Darriet, F.; Xumbo, B.; Milesi, P.; Thiria, J.; Bernard, V.; Toty, C.; Labbe, P.; Chandre, F. Insecticide resistance in disease vectors from Mayotte: An opportunity for integrated vector management. Parasit. Vectors. 2014, 7, 299. [Google Scholar] [CrossRef]
  41. Georghiou, G.P.; Ariaratnam, V.; Pasternak, M.E.; Lin, C.S. Organophosphorus multiresistance in Culex pipiens quinquefasciatus in California. J. Econ. Entomol. 1975, 68, 461–467. [Google Scholar] [CrossRef]
  42. Burtis, J.C.; Poggi, J.D.; McMillan, J.R.; Crans, S.C.; Campbell, S.R.; Isenberg, A.; Pulver, J.; Casey, P.; White, K.; Zondag, C.; et al. NEVBD pesticide resistance monitoring network: Establishing a centralized network to increase regional capacity for pesticide resistance detection and monitoring. J. Med. Entomol. 2021, 58, 787–797. [Google Scholar] [CrossRef] [PubMed]
  43. Sinegre, G.; Gaven, B.; Jullien, J.L. Comparative action of 31 insecticides on chlorpyrifos-sensitive and resistant Culex pipiens (L.) larvae in the South of France. Parassitologia 1977, 19, 63–72. [Google Scholar]
  44. Robert, L.L.; Olson, J.K. Effects of sublethal dosages of insecticides on Culex quinquefasciatus. J. Am. Mosq. Control Assoc. 1989, 5, 239–246. [Google Scholar] [PubMed]
  45. Ortega, A.N.; Marquetti, M.C.; Valdés, S.; García, F.A. Tolerance of Culex quinquefasciatus Say, 1823 (Diptera:Culicidae) to methoprene in Cuba. Mem. Inst. Oswaldo Cruz. 1991, 86, 493. [Google Scholar] [CrossRef] [PubMed]
  46. Paul, A.; Harrington, L.C.; Zhang, L.; Scott, J.G. Insecticide resistance in Culex pipiens from New York. J. Am. Mosq. Control Assoc. 2005, 21, 305–309. [Google Scholar] [CrossRef]
  47. Kamita, S.G.; Samra, A.I.; Liu, J.Y.; Cornel, A.J.; Hammock, B.D. Juvenile hormone (JH) esterase of the mosquito Culex quinquefasciatus is not a target of the JH analog insecticide methoprene. PLoS ONE 2011, 6, e28392. [Google Scholar] [CrossRef]
  48. Su, T.; Thieme, J.L.; Cheng, M.L. Impact of storage and handling temperatures on the activities of mosquito larvicides. J. Am. Mosq. Control Assoc. 2018, 34, 244–248. [Google Scholar] [CrossRef]
  49. Baruah, I.; Das, S.C. Evaluation of methoprene (Altosid) and diflubenzuron (Dimilin) for control of mosquito breeding in Tezpur (Assam). Indian J. Malariol. 1996, 33, 61–66. [Google Scholar]
  50. Su, T.; Thieme, J.; White, G.S.; Lura, T.; Mayerle, N.; Faraji, A.; Cheng, M.L.; Brown, M.Q. High Resistance to Bacillus sphaericus and susceptibility to other common pesticides in Culex pipiens (Diptera: Culicidae) from Salt Lake City, UT. J. Med. Entomol. 2019, 56, 506–513. [Google Scholar] [CrossRef]
  51. Vasquez, M.I.; Violaris, M.; Hadjivassilis, A.; Wirth, M.C. Susceptibility of Culex pipiens (Diptera: Culicidae) field populations in Cyprus to conventional organic insecticides, Bacillus thuringiensis subsp. israelensis, and methoprene. J. Med. Entomol. 2009, 46, 881–887. [Google Scholar] [CrossRef]
  52. Su, T.; Su, H. Evaluation on the activity and efficacy of Omniprene™ WSP and XWSP against the Southern House Mosquito Culex quinquefasciatus in simulated catch basins. J. Am. Mosq. Control Assoc. 2022, 38, 268–275. [Google Scholar] [CrossRef] [PubMed]
  53. Lopez, K.; Harbison, J.; Irwin, P.; Erkapic, A.; Holub, R.; Blanco, C.; Paskewitz, S.; Clifton, M.; Bartholomay, L. Extreme resistance to S-methoprene in field-collected Culex pipiens (Diptera: Culicidae) across the Chicago, IL region. Sci. Rep. 2024, 14, 18001. [Google Scholar] [CrossRef]
  54. Su, T.; Yu, J.S.; Zhang, Y.; Qian, X.; Su, H. Comparative bioactivity of S-methoprene and novel S-methobutene against mosquitoes (Diptera: Culicidae). J. Med. Entomol. 2023, 60, 1357–1363. [Google Scholar] [CrossRef] [PubMed]
  55. Ritchie, S.A.; Asnicar, M.; Kay, B.H. Acute and sublethal effects of (S)-methoprene on some Australian mosquitoes. J. Am. Mosq. Control Assoc. 1997, 13, 153–155. [Google Scholar]
  56. Aldridge, R.L.; Alto, B.W.; Connelly, C.R.; Okech, B.; Siegfried, B.; Linthicum, K.J. Lethal and sublethal concentrations of formulated larvicides against susceptible Aedes aegypti. J. Am. Mosq. Control Assoc. 2022, 38, 250–260. [Google Scholar] [CrossRef]
  57. Paul, A.; Harrington, L.C.; Scott, J.G. Evaluation of novel insecticides for control of dengue vector Aedes aegypti (Diptera: Culicidae). J. Med. Entomol. 2006, 43, 55–60. [Google Scholar] [CrossRef]
  58. Su, T.; Thieme, J.; Lura, T.; Cheng, M.L.; Brown, M.Q. Susceptibility profile of Aedes aegypti L. (Diptera: Culicidae) from Montclair, California, to commonly used pesticides, with note on resistance to pyriproxyfen. J. Med. Entomol. 2019, 56, 1047–1054. [Google Scholar] [CrossRef]
  59. Buei, K.; Ito, S.; Yamada, T.; Gamo, S.; Kato, M. The effect of a juvenile hormone mimic, methoprene, against mosquito larvae. Med. Entomol. Zool. 1975, 26, 105–111. [Google Scholar] [CrossRef]
  60. Sawby, R.; Klowden, M.J.; Sjogren, R.D. Sublethal effects of larval methoprene exposure on adult mosquito longevity. J. Am. Mosq. Control Assoc. 1992, 8, 290–292. [Google Scholar]
  61. Braga, I.A.; Mello, C.B.; Montella, I.R.; Lima, J.B.; Martins, A.J.; Medeiros, P.F.; Valle, D. Effectiveness of methoprene, an insect growth regulator, against temephos-resistant Aedes aegypti populations from different Brazilian localities, under laboratory conditions. J. Med. Entomol. 2005, 42, 830–837. [Google Scholar] [CrossRef]
  62. Ramirez-Lachmann, S.; Hart, J.; Su, T.; Latham, M.; Lesser, C. Comparative laboratory activity and semi-field efficacy of Omniprene® G and Altosid® pellets against Aedes aegypti. J. Am. Mosq. Control Assoc. 2024, 40, 162–168. [Google Scholar] [CrossRef]
  63. Braga, I.A.; Mello, C.B.; Peixoto, A.A.; Valle, D. Evaluation of methoprene effect on Aedes aegypti (Diptera: Culicidae) development in laboratory conditions. Mem. Inst. Oswaldo Cruz. 2005, 100, 435–440. [Google Scholar] [CrossRef]
  64. Fansiri, T.; Pongsiri, A.; Khongtak, P.; Nitatsukprasert, C.; Chittham, W.; Jaichapor, B.; Pathawong, N.; Kijchalao, U.; Tiangtrong, S.; Singkhaimuk, P.; et al. The impact of insect growth regulators on adult emergence inhibition and the fitness of Aedes aegypti field populations in Thailand. Acta Trop. 2022, 236, 106695. [Google Scholar] [CrossRef] [PubMed]
  65. Su, T. Comparative activity and efficacy of Sumilarv 0.5G and Altosid Xr briquet against Culex quinquefasciatus and Aedes aegypti in simulated catch basins. J. Am. Mosq. Control Assoc. 2023, 39, 173–182. [Google Scholar] [CrossRef] [PubMed]
  66. Ali, A.; Nayar, J.K.; Xue, R.D. Comparative toxicity of selected larvicides and insect growth regulators to a Florida laboratory population of Aedes albopictus. J. Am. Mosq. Control Assoc. 1995, 11, 72–76. [Google Scholar]
  67. Marcombe, S.; Farajollahi, A.; Healy, S.P.; Clark, G.G.; Fonseca, D.M. Insecticide resistance status of United States populations of Aedes albopictus and mechanisms involved. PLoS ONE 2014, 9, e101992. [Google Scholar] [CrossRef] [PubMed]
  68. Lau, K.W.; Chen, C.D.; Lee, H.L.; Low, V.L.; Sofian-Azirun, M. Bioefficacy of insect growth regulators against Aedes albopictus (Diptera: Culicidea) from Sarawak, Malaysia: A statewide survey. J. Econ. Entomol. 2018, 111, 1388–1394. [Google Scholar] [CrossRef]
  69. Elia-Amira, N.M.R.; Chen, C.D.; Low, V.L.; Lau, K.W.; Haziqah-Rashid, A.; Amelia-Yap, Z.H.; Lee, H.L.; Sofian-Azirun, M. Statewide efficacy assessment of insect growth regulators against Aedes albopictus (Diptera: Culicidae) in Sabah, Malaysia: An alternative control strategy? J. Med. Entomol. 2022, 59, 301–307. [Google Scholar] [CrossRef]
  70. Al-Sarar, A.S.; Al-Shahrani, D.; Bayoumi, A.E.; Yasser Abobakr, Y.A.; Hussein, H.I. Laboratory and field evaluation of some chemical and biological larvicides against Culex spp. (Diptera: Culicidae) immature stages. Int. J. Agric. Biol. 2011, 13, 115–119. [Google Scholar]
  71. Kawada, H.; Kohamma, T.; Aba, Y. Larvicidal activity of water-soluble granular formulation of the insect growth regulator, pyriproxyfen, against Culex mosquitoes. Jpn. J. Environ. Entomol. Zool. 1994, 6, 68–77. [Google Scholar] [CrossRef]
  72. Schaefer, C.H.; Mulligan, F.S. Potential for resistance to pyriproxyfen: A promising new mosquito larvicide. J. Am. Mosq. Control Assoc. 1991, 7, 409–411. [Google Scholar] [PubMed]
  73. Mulla, M.S.; Darwazeh, H.A.; Kennedy, B.; Dawson, D.M. Evaluation of new insect growth regulators against mosquitoes with notes on nontarget organisms. J. Am. Mosq. Control Assoc. 1986, 2, 314–320. [Google Scholar]
  74. Schaefer, C.H.; Miura, T.; Dupras, E.F.; Mulligan, F.S.; Wilder, W.H. Efficacy, nontarget effects, and chemical persistence of S-31183, a promising mosquito (Diptera: Culicidae) control agent. J. Econ. Entomol. 1988, 81, 1648–1655. [Google Scholar] [CrossRef] [PubMed]
  75. Kasai, S.; Shono, T.; Komagata, O.; Tsuda, Y.; Kobayashi, M.; Motoki, M.; Kashima, I.; Tanikawa, T.; Yoshida, M.; Tanaka, I.; et al. Insecticide resistance in potential vector mosquitoes for West Nile virus in Japan. J. Med. Entomol. 2007, 44, 822–829. [Google Scholar] [CrossRef]
  76. El-Shazly, M.M.; Refaie, B.M. Larvicidal effect of the juvenile hormone mimic pyriproxyfen on Culex pipiens. J. Am. Mosq. Control Assoc. 2002, 18, 321–328. [Google Scholar] [PubMed]
  77. Ahmed, M.A.I.; Vogel, C.F.A. The synergistic effect of octopamine receptor agonists on selected insect growth regulators on Culex quinquefasciatus Say (Diptera: Culicidae) mosquitoes. One Health. 2020, 10, 100138. [Google Scholar] [CrossRef]
  78. Al-Azab, A.M.; Shaheen, M.A.; Al-ghamdi, K.M.; Zaituo, A.A. The biological effects of Sumilarv and Flubex on dengue fever vector Aedes aegypti in Jeddah Governorate Saudi Arabia. Biosci. Biotechnol. Res. Asia. 2013, 10, 235–240. [Google Scholar] [CrossRef]
  79. Moura, L.; De Nadai, B.L.; Bernegossi, A.C.; Felipe, M.C.; Castro, G.B.; Corbi, J.J. Be quick or be dead: High temperatures reduce Aedes aegypti (Diptera: Culicidae) larval development time and pyriproxyfen larvicide efficiency in laboratory conditions. Int. J. Trop. Insect Sci. 2021, 41, 1667–1672. [Google Scholar] [CrossRef]
  80. Loh, P.Y.; Yap, H.H. Laboratory studies on the efficacy and sublethal effects of an insect growth regulator, pyriproxyfen (S-31183) against Aedes aegypti (Linnaeus). Trop. Biomed. 1989, 6, 7–12. [Google Scholar]
  81. Andrighetti, M.T.M.; Cerone, F.; Rigueti, M.; Galvani, K.C.; Macoris, M.D.L.D.G. Effect of pyriproxyfen in Aedes aegypti populations with different levels of susceptibility to the organophosphate temephos. Dengue Bulletin. 2008, 32, 186–198. [Google Scholar]
  82. Melo-Santos, M.A.V.; Varjal-Melo, J.J.M.; Araújo, A.P.; Gomes, T.C.S.; Paiva, M.H.S.; Regis, L.N.; Furtado, A.F.; Magalhaes, T.; Macoris, M.L.G.; Andrighetti, M.T.M.; et al. Resistance to the organophosphate temephos: Mechanisms, evolution and reversion in an Aedes aegypti laboratory strain from Brazil. Acta Trop. 2010, 113, 180–189. [Google Scholar] [CrossRef] [PubMed]
  83. Rodríguez Coto, M.M.; Terán Zavala, M.D.C.; Bisset Lazcano, J.A.; Leyva, Y.R.; Pacheco, L.F.; Fuentes Lopez, I. Efficacy of pyriproxyfen in reference strains of Aedes aegypti susceptible and resistant to temephos. Rev. Cubana Med. Trop. 2013, 65, 339–349. [Google Scholar]
  84. Terán Zavala, M.D.C.; Rodríguez Coto, M.M.; Leyva, Y.R.; Bisset Lazcano, J.A. Evaluation of temephos and pyriproxyfen against Aedes aegypti (Diptera: Culicidae) from Guayaquil, Ecuador. Rev. Cubana Med. Trop. 2014, 66, 71–83. [Google Scholar]
  85. Estrada, J.G.; Mulla, M.S. Evaluation of two new insect growth regulators against mosquitoes in the laboratory. J. Am. Mosq. Control Assoc. 1986, 2, 57–60. [Google Scholar] [PubMed]
  86. Itoh, T.; Kawada, H.; Abe, A.; Eshita, Y.; Rongsriyam, Y.; Igarashi, A. Utilization of bloodfed females of Aedes aegypti as a vehicle for the transfer of the insect growth regulator pyriproxyfen to larval habitats. J. Am. Mosq. Control Assoc. 1994, 10, 344–347. [Google Scholar] [PubMed]
  87. Leyva, R.Y.; Rodríguez Coto, M.M.; Bisset Lazcano, J.A.; Pérez Insueta, O.; Sánchez Valdés, L. Effect of pyriproxyfen for the Aedes (S) aegypti control (Diptera: Culicidae) in strains with various degrees of temephos resistance. Rev. Cubana Med. Trop. 2010, 62, 224–229. [Google Scholar]
  88. Marcombe, S.; Darriet, F.; Agnew, P.; Etienne, M.; Yp-Tcha, M.M.; Yébakima, A.; Corbel, V. Field efficacy of new larvicide products for control of multi-resistant Aedes aegypti populations in Martinique (French West Indies). Am. J. Trop. Med. Hyg. 2011, 84, 118–126. [Google Scholar] [CrossRef]
  89. Gómez, A.; Seccacini, E.; Zerba, E.; Licastro, S. Comparison of the insecticide susceptibilities of laboratory strains of Aedes aegypti and Aedes albopictus. Mem. Inst. Oswaldo Cruz. 2011, 106, 993–996. [Google Scholar] [CrossRef]
  90. Marcombe, S.; Chonephetsarath, S.; Thammavong, P.; Brey, P.T. Alternative insecticides for larval control of the dengue vector Aedes aegypti in Lao PDR: Insecticide resistance and semi-field trial study. Parasit. Vectors. 2018, 11, 616. [Google Scholar] [CrossRef]
  91. Campos, K.B.; Alomar, A.A.; Eastmond, B.H.; Obara, M.T.; Dias, L.D.S.; Rahman, R.U.; Alto, B.W. Assessment of insecticide resistance of Aedes aegypti (Diptera: Culicidae) populations to insect growth regulator pyriproxyfen, in the northeast region of Brazil. J. Vector. Ecol. 2023, 48, 12–18. [Google Scholar] [CrossRef]
  92. Darriet, F.; Corbel, V. Laboratory evaluation of pyriproxyfen and spinosad, alone and in combination, against Aedes aegypti larvae. J. Med. Entomol. 2006, 43, 1190–1194. [Google Scholar] [CrossRef] [PubMed]
  93. Moura, L.; De Nadai, B.L.; Corbi, J.J. One does not simply apply larvicides: Aedes aegypti from Araraquara (Brazil) has reduced susceptibility to pyriproxyfen. Vet. Parasit. Reg. Stud. Rep. 2023, 41, 100875. [Google Scholar] [CrossRef]
  94. Seccacini, E.; Lucia, A.; Harburguer, L.; Zerba, E.; Licastro, S.; Masuh, H. Effectiveness of pyriproxyfen and diflubenzuron formulations as larvicides against Aedes aegypti. J. Am. Mosq. Control Assoc. 2008, 24, 398–403. [Google Scholar] [CrossRef]
  95. Carvalho, B.L.; Germano, R.N.L.; Braga, K.M.L.; Araújo, E.R.F.; Rocha, D.A.; Obara, M.T. Susceptibility of Aedes aegypti populations to pyriproxyfen in the Federal District of Brazil. Rev. Soc. Bras. Med. Trop. 2020, 53, e20190489. [Google Scholar] [CrossRef]
  96. Campos, K.B.; Martins, A.J.; Rodovalho, C.M.; Bellinato, D.F.; Dias, L.D.S.; Macoris, M.L.D.G.; Andrighetti, M.T.M.; Lima, J.B.P.; Obara, M.T. Assessment of the susceptibility status of Aedes aegypti (Diptera: Culicidae) populations to pyriproxyfen and malathion in a nation-wide monitoring of insecticide resistance performed in Brazil from 2017 to 2018. Parasit. Vectors. 2020, 13, 531. [Google Scholar] [CrossRef]
  97. Ohashi, K. Control of mosquito larvae in catch basins using pyriproxyfen and the mechanism underlying residual efficacy. Med. Entomol. Zool. 2017, 68, 127–135. [Google Scholar] [CrossRef]
  98. Su, X.; Guo, Y.; Deng, J.; Xu, J.; Zhou, G.; Zhou, T.; Li, Y.; Zhong, D.; Kong, L.; Wang, X.; et al. Fast emerging insecticide resistance in Aedes albopictus in Guangzhou, China: Alarm to the dengue epidemic. PLoS Negl. Trop. Dis. 2019, 13, e0007665. [Google Scholar] [CrossRef]
  99. Dell Chism, B.; Apperson, C.S. Horizontal transfer of the insect growth regulator pyriproxyfen to larval microcosms by gravid Aedes albopictus and Ochlerotatus triseriatus mosquitoes in the laboratory. Med. Vet. Entomol. 2003, 17, 211–220. [Google Scholar] [CrossRef]
  100. Suman, D.S.; Wang, Y.; Dong, L.; Gaugler, R. Effects of larval habitat substrate on pyriproxyfen efficacy against Aedes albopictus (Diptera: Culicidae). J. Med. Entomol. 2013, 50, 1261–1266. [Google Scholar] [CrossRef]
  101. Lin, L.Q.; Chen, Y.H.; Tian, Y.F.; Chen, Y.S.; Zheng, Z.Y.; Wu, J.X.; Hu, F.; Wu, C.; Xie, L.H. Study on the cross-resistance of Aedes albopictus (Skuse) (Diptera: Culicidae) to deltamethrin and pyriproxyfen. Parasit. Vectors. 2024, 17, 403. [Google Scholar] [CrossRef] [PubMed]
  102. Sullivan, J.J.; Goh, K.S. Environmental fate and properties of pyriproxyfen. J. Pesticide Sci. 2008, 33, 339–350. [Google Scholar] [CrossRef]
  103. Methoprene: PubChem Compound Summary for CID 5366546. National Center for Biotechnology Information (NCBI). Available online: https://pubchem.ncbi.nlm.nih.gov/compound/Methoprene (accessed on 20 February 2025).
  104. Nagy, K.; Duca, R.C.; Lovas, S.; Creta, M.; Scheepers, P.T.; Godderis, L.; Ádám, B. Systematic review of comparative studies assessing the toxicity of pesticide active ingredients and their product formulations. Environ. Res. 2020, 181, 108926. [Google Scholar] [CrossRef] [PubMed]
  105. Pyriproxyfen: PubChem Compound Summary for CID 91753. National Center for Biotechnology Information (NCBI). Available online: https://pubchem.ncbi.nlm.nih.gov/compound/Pyriproxyfen (accessed on 20 February 2025).
  106. Khan, H.A.A. Posttreatment temperature influences toxicity of insect growth regulators in Musca domestica. Parasitol. Res. 2021, 120, 435–441. [Google Scholar] [CrossRef]
  107. Devillers, J. Fate and ecotoxicological effects of pyriproxyfen in aquatic ecosystems. Environ. Sci. Pollut. Res. 2020, 27, 16052–16068. [Google Scholar] [CrossRef]
  108. Benedict, M.Q.; Levine, R.S.; Hawley, W.A.; Lounibos, L.P. Spread of the Tiger: Global risk of invasion by the mosquito Aedes albopictus. Vector-Borne Zoonotic Dis. 2007, 7, 76–85. [Google Scholar] [CrossRef]
  109. Kotsakiozi, P.; Richardson, J.B.; Pichler, V.; Favia, G.; Martins, A.J.; Urbanelli, S.; Armbruster, P.A.; Caccone, A. Population genomics of the Asian tiger mosquito, Aedes albopictus: Insights into the recent worldwide invasion. Ecol. Evol. 2017, 7, 10143–10157. [Google Scholar] [CrossRef]
  110. Finney, D.J. Probit Analysis; Cambridge University Press: Cambridge, UK, 1971. [Google Scholar]
  111. Robertson, J.L.; Savin, N.E.; Russell, R.M.; Preisler, H.K. Bioassays with Arthropods; CRC Press: Boca Raton, FL, USA, 2007. [Google Scholar]
  112. Wheeler, M.W.; Park, R.M.; Bailey, A.J. Comparing median lethal concentration values using confidence interval overlap or ratio tests. Environ. Toxic Chem. 2006, 25, 1441. [Google Scholar] [CrossRef]
Figure 1. PRISMA flow chart of the publication assessment and inclusion process. No automation tools were used.
Figure 1. PRISMA flow chart of the publication assessment and inclusion process. No automation tools were used.
Tropicalmed 10 00087 g001
Figure 2. Distribution of IE50, IE90, and IE95 values (in ppm) reported in the literature (open circles), and DL combined effect values (red-filled circles).
Figure 2. Distribution of IE50, IE90, and IE95 values (in ppm) reported in the literature (open circles), and DL combined effect values (red-filled circles).
Tropicalmed 10 00087 g002
Table 1. Summary of ANOVA results for the subgroup analysis of Culex spp. complex mosquitoes. A p-value for pyriproxyfen at IE95 could not be computed due to the low number of available studies.
Table 1. Summary of ANOVA results for the subgroup analysis of Culex spp. complex mosquitoes. A p-value for pyriproxyfen at IE95 could not be computed due to the low number of available studies.
methoprene
Culex pipiens
IE50IE90IE95
Between groups (SS)2.340.000.13
Within groups (SS)25.1413.122.46
Number of studies24124
F-statistic0.090.000030.05108
Between groups (df)211
Within groups (df)21102
Between groups p-value0.310.990.72
pyriproxyfen
IE50IE90IE95
Between groups (SS)4.570.770.00
Within groups (SS)13.152.381.68
Number of studies1253
F-statistic0.350.320.00
Between groups (df)210
Within groups (df)932
Between groups p-value0.100.38
Table 2. Summary of heterogeneity across studies (Cochrane’s Q, I2, T2, and T) for each IGR/species/EI value pairing with >2 publications. T represents the standard deviation of true effect sizes on the log scale, and unlogged T represents the fold change in effect sizes across studies (10T).
Table 2. Summary of heterogeneity across studies (Cochrane’s Q, I2, T2, and T) for each IGR/species/EI value pairing with >2 publications. T represents the standard deviation of true effect sizes on the log scale, and unlogged T represents the fold change in effect sizes across studies (10T).
methoprene
Culex pipiensAedes aegyptiAedes albopictus
IE50IE90IE95IE50IE90IE95IE50IE90IE95
Q736.52103.154.246807.87245.271183.47201.80
pq0.000.000.240.000.000.000.00
df2311316773
I296.88%89.34%29.32%99.76%97.15%99.41%98.51%
T20.340.170.011.130.200.380.20
T0.580.410.081.060.440.620.44
Fold change in effect size (10T)3.832.571.2011.592.784.172.79
pyriproxyfen
IE50IE90IE95IE50IE90IE95IE50IE90IE95
Q2373.51120.1118.9611,381.13567.015113.516448.14521.463.03
pq0.000.000.000.000.000.000.000.000.22
df1142254121032
I299.54%96.67%89.45%99.78%99.29%99.77%99.84%99.42%34.09%
T20.130.150.060.190.520.451.573.110.02
T0.360.390.240.440.720.671.251.760.13
Fold change in effect size (10T)2.292.451.752.735.274.7217.9357.971.34
Table 3. Results of Egger’s regression on all species/IGR/IE pairings. Only the Ae. albopictus/methoprene/IE50 pairing was significant (p = 0.043). The Cx. pipiens/pyriproxyfen/IE90 pairing had a p-value of 0.055, indicating marginal funnel plot asymmetry. All other funnel plots were symmetrical.
Table 3. Results of Egger’s regression on all species/IGR/IE pairings. Only the Ae. albopictus/methoprene/IE50 pairing was significant (p = 0.043). The Cx. pipiens/pyriproxyfen/IE90 pairing had a p-value of 0.055, indicating marginal funnel plot asymmetry. All other funnel plots were symmetrical.
methoprene
Culex pipiensAedes aegyptiAedes albopictus
IE50IE90IE95IE50IE90IE95IE50IE90IE95
Intercept0.990.231.219.86−5.9811.69−16.242.89−1.59
SE2.192.261.098.795.116.3514.15
p-value0.6580.9220.3820.2790.2860.0430.857
Lower 95% CI−3.55−4.75−2.26−8.76−18.07−31.26−42.14
Upper 95% CI5.535.214.6828.486.11−1.2247.92
t-test0.450.101.111.12−1.17−2.560.20
pyriproxyfen
IE50IE90IE95IE50IE90IE95IE50IE90IE95
Intercept−0.22−12.8210.911.9834.209.519.73−7.93−1.55
SE6.154.187.355.0318.088.9014.2415.870.63
p-value0.9720.0550.3770.6980.1550.3080.5110.6670.244
Lower 95% CI−13.76−24.43−20.72−8.38−15.99−9.89−21.99−58.44−4.25
Upper 95% CI13.32−1.2042.5412.3384.3928.9141.4542.591.14
t-test−0.04−3.061.480.391.891.070.68−0.50−2.48
Table 4. Summary statistics (minimum, maximum, and IQR), as well as DerSimonian and Laird (DL) combined effects values ±95% CI for the IGRs pyriproxyfen and methoprene and the species Cx. pipiens, Ae. aegypti, and Ae. albopictus at IE50, IE90, and/or IE95.
Table 4. Summary statistics (minimum, maximum, and IQR), as well as DerSimonian and Laird (DL) combined effects values ±95% CI for the IGRs pyriproxyfen and methoprene and the species Cx. pipiens, Ae. aegypti, and Ae. albopictus at IE50, IE90, and/or IE95.
methoprene
Culex pipiensAedes aegyptiAedes albopictus
IE50 (ppb)IE90 (ppb)IE95 (ppb)IE50 (ppb)IE90 (ppb)IE95 (ppb)IE50 (ppb)IE90 (ppb)IE95 (ppb)
Number of studies241241782842
Minimum0.0051.3902.2900.0100.3140.0660.1408.10010.000
  25% Percentile0.1454.4902.5930.2552.8670.0660.71512.83010.000
  Median0.53213.7604.5500.8897.7892.0831.75035.50047.500
  75% Percentile1.37819.02014.0801.7129.6974.1008.15057.50085.000
Maximum3.500119.00016.9002.78010.5004.10010.00062.00085.000
DL Combined Effect0.42912.3164.5020.5054.5590.5071.81827.68947.285
  Lower CI (95%)0.2325.8522.6170.2131.5952.06 × 10−120.5376.6842.56 × 10−4
  Upper CI (95%)0.79025.9207.7461.20113.0331.25 × 10116.154114.7058.75 × 106
pyriproxyfen
Culex pipiensAedes aegyptiAedes albopictus
IE50 (ppb)IE90 (ppb)IE95 (ppb)IE50 (ppb)IE90 (ppb)IE95 (ppb)IE50 (ppb)IE90 (ppb)IE95 (ppb)
Number of studies1253265131143
Minimum0.0050.3000.0630.0010.0090.0100.0090.3760.217
  25% Percentile0.0180.3060.0630.0190.0650.0580.0160.4290.217
  Median0.0450.4000.1600.0540.1620.3200.07394.7900.490
  75% Percentile0.0900.9900.1600.2540.2032.1500.200861.8000.668
Maximum0.4201.5500.1603.0000.24531.00044.0001086.0000.668
DL Combined Effect0.0480.4820.1160.0550.0920.3390.14814.3300.543
  Lower CI (95%)0.0250.2060.0300.0230.0170.0800.0210.0240.176
  Upper CI (95%)0.0951.1260.4470.1280.4941.4371.0538713.3551.671
Table 5. Sensitivity analyses for each species/IGR/IE pairing. Sensitivity was assessed in three ways: (1) By removing studies with imputed 95%CIs and recalculating the combined effect size, (2) by identifying and removing outliers and recalculating the combined effect size, and (3) by calculating a geometric mean with 95% CIs. If no studies were imputed or no outliers were detected, a new combined effect size was not calculated.
Table 5. Sensitivity analyses for each species/IGR/IE pairing. Sensitivity was assessed in three ways: (1) By removing studies with imputed 95%CIs and recalculating the combined effect size, (2) by identifying and removing outliers and recalculating the combined effect size, and (3) by calculating a geometric mean with 95% CIs. If no studies were imputed or no outliers were detected, a new combined effect size was not calculated.
methoprene
Culex pipiensAedes aegyptiAedes albopictus
IE50 (ppb)IE90 (ppb)IE95 (ppb)IE50 (ppb)IE90 (ppb)IE95 (ppb)IE50 (ppb)IE90 (ppb)IE95 (ppb)
Total number of studies241241782842
  DL combined effect 0.42912.3164.5020.5054.5590.5071.81827.68947.285
        Lower CI (95%)0.2325.8522.6170.2131.5952.06 × 10−120.5376.6842.56 × 10−4
Upper CI (95%)0.79025.9207.7461.20113.0331.25 × 10116.154114.7058.75 × 106
Imputed studies removed
Number of studies removed1240610200
DL combined effect 0.48510.4790.3484.2272.404
Lower CI (95%)0.1833.6190.1081.2230.445
Upper CI (95%)1.28230.3411.11714.61212.980
Outliers removed
Number of studies removed000120000
DL combined effect0.6609.208
Lower CI (95%)0.3188.005
Upper CI (95%)1.37210.592
Geometric mean0.36511.9105.2480.5044.5070.5201.80827.79029.150
Lower CI (95%)0.1845.5771.3340.2121.5602.11 × 10−150.5366.7453.63 × 10−5
Upper CI (95%)0.72625.45020.6501.19713.0201.28 × 1086.096114.5002.34 × 107
pyriproxyfen
Culex pipiensAedes aegyptiAedes albopictus
IE50 (ppb)IE90 (ppb)IE95 (ppb)IE50 (ppb)IE90 (ppb)IE95 (ppb)IE50 (ppb)IE90 (ppb)IE95 (ppb)
Total number of studies1253265131143
DL combined effect 0.0480.4820.1160.0550.0920.3390.14814.3300.543
Lower CI (95%)0.0250.2060.0300.0230.0170.0800.0210.0240.176
Upper CI (95%)0.0951.1260.4470.1280.4941.4371.0538713.3551.67
Imputed studies removed
Number of studies removed311511000
DL combined effect 0.0500.5420.0980.0500.0720.294
Lower CI (95%)0.0200.1700.0000.0190.0070.063
Upper CI (95%)0.1261.72536.4780.1330.7011.385
Outliers removed
Number of studies removed010000000
DL combined effect0.347
Lower CI (95%)0.266
Upper CI (95%)0.453
Geometric mean0.0440.4780.1170.0530.0920.3310.14714.5900.414
Lower CI (95%)0.0210.2070.0310.0230.0170.080.0210.0240.098
Upper CI (95%)0.0911.1060.4460.1230.4941.431.0438964.0001.753
Table 6. Certainty of evidence assessment for each species/IGR/IE value pairing. Subgroup pairings with I2 greater than 75% were downgraded. Subgroup pairings with a 95% UCI more than 3-fold the DL combined effect values were downgraded (downgrade denoted by “↓”). ↓* = no I2 value could be calculated due to the small number of publications included. ↓ = no Egger’s regression could be conducted due to the small number of publications included. ↓ = p-value of 0.055 indicates the possibility of publication bias; subgroup was not downgraded.
Table 6. Certainty of evidence assessment for each species/IGR/IE value pairing. Subgroup pairings with I2 greater than 75% were downgraded. Subgroup pairings with a 95% UCI more than 3-fold the DL combined effect values were downgraded (downgrade denoted by “↓”). ↓* = no I2 value could be calculated due to the small number of publications included. ↓ = no Egger’s regression could be conducted due to the small number of publications included. ↓ = p-value of 0.055 indicates the possibility of publication bias; subgroup was not downgraded.
methoprene
Culex pipiensAedes aegyptiAedes albopictus
IE50IE90IE95IE50IE90IE95IE50IE90IE95
Risk of bias
Inconsistency (I2 > 75%)↓*↓*
Imprecision (UCI > 3 × IE)
Indirectness
Publication Bias (p < 0.05)
Final Certainty RatingModerateModerateHighModerateModerateVery LowVery LowLowVery Low
pyriproxyfen
IE50IE90IE95IE50IE90IE95IE50IE90IE95
Risk of bias
Inconsistency (I2 > 75%)
Imprecision (UCI > 3 × IE)
Indirectness
Publication Bias (p < 0.05)
Final Certainty RatingModerateModerateLowModerateLowLowLowLowModerate
Table 7. Summary of RR IE50 for included publications. Resistance ratios were calculated by dividing the reference IE50 values reviewed here with the DL combined effect IE50 value.
Table 7. Summary of RR IE50 for included publications. Resistance ratios were calculated by dividing the reference IE50 values reviewed here with the DL combined effect IE50 value.
Number (%) of Publications at RR IE50
Culex pipiensAedes aegyptiAedes albopictus
RR<11–55–10>10<11–55–10>10<11–55–10>10
methoprene10 (42%)12 (50%)2 (8%)0 (0%)7 (41%)8 (47%)2 (12%)0 (0%)4 (50%)2 (25%)2 (25)%0 (0%)
pyriproxyfen7 (58%)4 (33%)1 (8%)0 (0%)13 (50%)7 (27%)3 (12%)3 (12%)8 (73%)1 (9%)0 (0%)2 (18%)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Clifton, M.E.; Lopez, K. Assessing Insect Growth Regulator Resistance Using Bioassays: A Systematic Review and Meta-Analysis of Methoprene and Pyriproxyfen Inhibition of Emergence in Three Vector Mosquito Species. Trop. Med. Infect. Dis. 2025, 10, 87. https://doi.org/10.3390/tropicalmed10040087

AMA Style

Clifton ME, Lopez K. Assessing Insect Growth Regulator Resistance Using Bioassays: A Systematic Review and Meta-Analysis of Methoprene and Pyriproxyfen Inhibition of Emergence in Three Vector Mosquito Species. Tropical Medicine and Infectious Disease. 2025; 10(4):87. https://doi.org/10.3390/tropicalmed10040087

Chicago/Turabian Style

Clifton, Mark E., and Kristina Lopez. 2025. "Assessing Insect Growth Regulator Resistance Using Bioassays: A Systematic Review and Meta-Analysis of Methoprene and Pyriproxyfen Inhibition of Emergence in Three Vector Mosquito Species" Tropical Medicine and Infectious Disease 10, no. 4: 87. https://doi.org/10.3390/tropicalmed10040087

APA Style

Clifton, M. E., & Lopez, K. (2025). Assessing Insect Growth Regulator Resistance Using Bioassays: A Systematic Review and Meta-Analysis of Methoprene and Pyriproxyfen Inhibition of Emergence in Three Vector Mosquito Species. Tropical Medicine and Infectious Disease, 10(4), 87. https://doi.org/10.3390/tropicalmed10040087

Article Metrics

Back to TopTop